Track topics on Twitter Track topics that are important to you
Infuseon Therapeutics and OncoSynergy are teaming up to evaluate the latter’s monoclonal pan-CD29 antibody OS2966, delivered using Infuseon’s Cleveland Multiport Catheter™ (CMC), for the potential treatment of glioblastoma. The firms’ strategic alliance aims to establish proof of concept that OS2966 can be delivered directly to the brain using the CMC, prior to considering a Phase I study for the glioblastoma indication. OncoSynergy is a University of California, San Francisco (UCSF) spin-out founded in 2011 to develop anticancer resistance mechanism inhibitors (RMIs). Lead candidate OS2966 is a first-in-class humanized, deimmunized antibody, which the firm says exhibits multiple mechanisms of action and has demonstrated significant efficacy in multiple models of aggressive and metastatic solid tumor types. OS2966 has been granted orphan drug designation by the FDA for the treatment of glioblastoma and ovarian cancer. OncoSynergy is headquartered at Johnson & Johnson Innovation’s JLABS incubator in South San Francisco. "We ...NEXT ARTICLE
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...
Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...